To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00191191 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Pemetrexed 500 mg/m2
DRUG: Pemetrexed 1000 mg/m2

Sponsor

Eli Lilly and Company